Osem ups Tivall stake

Osem Investments Ltd. exercised its option to buy another 7% of Tivall for NIS 70.9m. in an effort to increase its product potential and international reach.

By SHARON WROBEL
March 16, 2006 07:13
osem 88

osem 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Osem Investments Ltd. exercised its option to buy another 7 percent of Tivall for NIS 70.9 million in an effort to increase its product potential and international reach. As a result, Osem now holds 58% of Tivall and its fully owned subsidiary Sabra Salad Food Industries. Osem said the acquired stake would contribute NIS 3m. to NIS 4m. to the company's net profits in 2006. Under the agreement, Osem has a seven-year put and call option to acquire the remaining 42% of Tivall it does not already own.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS